What’s happening with the trials: despite chatter online about an active Phase 2B, public company updates and press coverage point to a Phase 2a program with an extension for some participants that runs through around December 2025; there is no clear, registered Phase ...
PP405
PP405 is a small, topical molecule born out of UCLA labs and now being developed by Pelage Pharmaceuticals to tackle hair loss by reawakening dormant hair follicles. Unlike drugs that only slow shedding, PP405 aims to flip a cellular switch so follicl...
PP405PP405 just cleared a meaningful early hurdle: Pelage announced positive Phase 2a topline results, and the company says it plans to move into later stage studies. Below I make straightforward predictions, with the reasoning behind each. Availability , year...
PP405
PP405Quick take: PP405 is a new, investigational topical that aims to reactivate dormant follicle stem cells, a different tactic from the familiar toolkit of minoxidil, finasteride and PRP. Early human work looks promising, but this is still a therapy ...
PP405Pelage’s PP405 started as a UCLA born idea about reawakening dormant hair follicle stem cells, and lately it has moved rapidly from bench to bedside. The molecule targets a metabolic “switch” in follicle stem cells, a different tactic than hormone blocking d...
PP405
Daily Motivation